Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates
09:37am, Tuesday, 04'th Nov 2025
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.1 per share a year ago.
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
07:00am, Tuesday, 04'th Nov 2025
Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
07:00am, Friday, 31'st Oct 2025
PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
07:00am, Thursday, 23'rd Oct 2025
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025,
Amicus Therapeutics: Turning The Corner To Profitability With 2 Developing Therapies
08:47pm, Wednesday, 22'nd Oct 2025
Amicus Therapeutics remains a Buy, supported by strong momentum in Galafold and Pombiliti/Opfolda, both with blockbuster potential. FOLD's Galafold leads in Fabry disease as the first oral precision m
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy
01:01pm, Tuesday, 07'th Oct 2025
Amicus Therapeutics (FOLD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns
10:26am, Monday, 06'th Oct 2025
Broker upgrades fuel optimism for Amicus Therapeutics, Micron and General Dynamics as earnings outlook strengthens.
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
10:41am, Thursday, 02'nd Oct 2025
Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.
3 Of My Favorite Biotech Stocks Under $10
01:15pm, Monday, 29'th Sep 2025
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
12:31pm, Thursday, 25'th Sep 2025
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?
10:36am, Friday, 19'th Sep 2025
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength
Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
06:06pm, Tuesday, 09'th Sep 2025
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 3:20 PM EDT Company Participants Sebastien Martel - Chief Business Officer Jeffrey Ca
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
09:00am, Monday, 08'th Sep 2025
Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling
In NCLA Amicus Win, en Banc Federal Circuit Rules Trump's Emergency Tariffs Are Unlawful
09:06pm, Friday, 29'th Aug 2025
V.O.S. Selections, Inc.; Plastic Services and Products, LCC, d/b/a Genova Pipe; MicroKits, LCC; FishUSA Inc.; Terry Precision Cycling LLC v. President Donald J. Trump, et al. V.O.S. Selections, Inc.;
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
07:00am, Friday, 29'th Aug 2025
PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i
